First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo . This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 we...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Whan Park, Neunggyu Park, Hukeun Lee, Sung Hee Hong, Song-Jae Lee, Seong-Won Song, Kyung Kim, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Do-Hyun Nam, Jeong-Won Lee, Keunchil Park, Kyoung-Mee Kim, Jeeyun Lee
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publishing 2020-06-01
סדרה:Therapeutic Advances in Medical Oncology
גישה מקוונת:https://doi.org/10.1177/1758835920926796
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים